|
 |
 |
| Plenary Session I |
Natcher Conference Center
Wednesday, October 16
8:30 a.m. to 10:30 a.m. |
|
| |
| Welcoming Remarks |
Main Auditorium |
| Dr. Elias Zerhouni, Director
of NIH |
| |
|
| Biodefense: A New NIH
Mission |
Main Auditorium |
| Chaired by Thomas J. Kindt, NIAID |
|
Recent events in the country have
given a new mandate to the NIH. The three presentations will:
1) highlight the past year's progress in the development
of diagnostics, vaccines and therapeutics to combat agents
of potential bioterrorism;
2) discuss the human reactions to the type of stress induced
by bioterrorism; and
3) delineate the role of the FDA in bringing to the public
vaccines to combat fears and reduce the potential harm of
deliberately-introduced infectious agents.
|
| Thomas J. Kindt, NIAID |
Introduction |
| Anthony Fauci, NIAID |
Progress and Challenges in Biodefense
Research |
| Dennis Charney, NIMH |
Coping with Stress and Anxiety in
Uncertain Times |
| Karen Elkins, CBER, FDA |
Vaccination as a Biodefense Strategy:
Risks, Benefits, and Lots of Challenges |
|
|
| |
|
